Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement

Kevin M. Friedman, Laura E. Devillier, Steven A. Feldman, Steven A. Rosenberg, Mark E. Dudley

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment of patients with adoptive T-cell therapy requires expansion of unique tumor-infiltrating lymphocyte (TIL) cultures from single-cell suspensions processed from melanoma biopsies. Strategies which increase the expansion and reliability of TIL generation from tumor digests are necessary to improve access to TIL therapy. Previous studies have evaluated artificial antigen presenting cells for their antigen-specific and costimulatory properties. We investigated engineered cells for costimulatory enhancement (ECCE) consisting of K562 cells that express 4-1BBL in the absence of artificial antigen stimulation. ECCE accelerated TIL expansion and significantly improved TIL numbers (P=0.001) from single-cell melanoma suspensions. TIL generated with ECCE contain significantly more CD8 +CD62L + and CD8 +CD27 + T cells then comparable interleukin-2-expanded TIL and maintained antitumor reactivity. Moreover, ECCE improved TIL expansion from nonmelanoma-cell suspensions similar to that seen with melanoma tumors. These data demonstrate that the addition of ECCE to TIL production will enable the treatment of patients that are ineligible using current methods.

Original languageEnglish (US)
Pages (from-to)651-661
Number of pages11
JournalJournal of Immunotherapy
Volume34
Issue number9
DOIs
StatePublished - Nov 2011

Keywords

  • adoptive immunotherapy
  • costimulation
  • tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement'. Together they form a unique fingerprint.

Cite this